Ursula J Buchholz

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Live vaccines for human metapneumovirus designed by reverse genetics
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6505, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Expert Rev Vaccines 5:695-706. 2006
  2. pmc Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo
    Quynh N Pham
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:15114-22. 2005
  3. pmc Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA
    J Virol 83:1969-80. 2009
  4. pmc Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002105. 2011
  5. pmc Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 5:e15017. 2010
  6. pmc Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 79:6588-97. 2005
  7. pmc Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Proc Natl Acad Sci U S A 101:9804-9. 2004
  8. pmc Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates
    Stephane Biacchesi
    National Institutes of Health, NIAID, Laboratory of Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:12608-13. 2005
  9. pmc Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 385:169-82. 2009
  10. ncbi request reprint Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Live vaccines for human metapneumovirus designed by reverse genetics
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6505, 50 South Dr MSC 8007, Bethesda, MD 20892 8007, USA
    Expert Rev Vaccines 5:695-706. 2006
    ..Additional modifications to provide improved vaccines will also be discussed...
  2. pmc Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo
    Quynh N Pham
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:15114-22. 2005
    ..Both chimeras were comparable to wild-type HMPV in immunogenicity and protective efficacy. Thus, the P chimera is a promising live HMPV vaccine candidate that paradoxically combines improved growth in vitro with attenuation in vivo...
  3. pmc Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA
    J Virol 83:1969-80. 2009
    ..In contrast, in the absence of NS2, there was an early, transient innate response involving moderate levels of IFN, IL-6, and CXCL10 that restricted virus replication and prevented disease...
  4. pmc Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002105. 2011
    ..We propose that inefficient migration of HRSV- and HMPV-stimulated DC to lymphatic tissue contributes to reduced adaptive responses to these viruses...
  5. pmc Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 5:e15017. 2010
    ..One causative factor is thought to be viral interference with dendritic cell (DC)-mediated stimulation of CD4+ T cells...
  6. pmc Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 79:6588-97. 2005
    ..The HMPV rdeltaM2-2 virus is a promising and highly attenuated HMPV vaccine candidate...
  7. pmc Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Proc Natl Acad Sci U S A 101:9804-9. 2004
    ....
  8. pmc Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates
    Stephane Biacchesi
    National Institutes of Health, NIAID, Laboratory of Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 79:12608-13. 2005
    ..The deltaG and deltaM2-2 viruses are promising vaccine candidates that are based on independent mechanisms of attenuation and are appropriate for clinical evaluation...
  9. pmc Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3
    Cyril Le Nouen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 385:169-82. 2009
    ..Maturation by these viruses was anti-apoptotic. Inefficient infection of IDC and sub-optimal maturation might result in reduced immune responses, but these effects would be common to all three viruses rather than specific to HRSV...
  10. ncbi request reprint Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004
    ..We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease...
  11. ncbi request reprint Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, NIAID, NIH, DHHS, Bethesda, MD 20892 8007, USA
    Virology 345:492-501. 2006
    ..Also, although the SH protein of HMPV is a virion protein that is much larger than its counterparts in previously studied paramyxoviruses, it does not appear to be a significant neutralization or protective antigen...
  12. pmc Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
    J Virol 78:12877-87. 2004
    ..This indicates that SH is completely dispensable in vivo and that its deletion does not confer an attenuating effect, at least in this rodent model...
  13. pmc Human metapneumovirus SH and G glycoproteins inhibit macropinocytosis-mediated entry into human dendritic cells and reduce CD4+ T cell activation
    Cyril Le Nouen
    RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 88:6453-69. 2014
    ..This study describes a previously unknown mechanism of virus immune evasion...
  14. pmc Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells
    Shirin Munir
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    J Virol 82:8780-96. 2008
    ..The observed suppression of DC maturation may result in decreased antigen presentation and T-lymphocyte activation, leading to incomplete and/or weak immune responses that might contribute to RSV reinfection...
  15. pmc Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    J Virol 80:5798-806. 2006
    ..These results suggest that cleavage activation is not a major determinant of HMPV virulence...
  16. pmc Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection
    Bo Liang
    RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 88:4237-50. 2014
    ..Vector passaged in vitro accumulated mutations in the HN open reading frame, causing a dramatic increase in plaque size that may have implications for vaccine production and immunogenicity...
  17. ncbi request reprint Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Building 50, Room 6505, 50 South Drive, MSC 8007 Bethesda, MD 20892 8007, USA
    J Virol Methods 128:192-7. 2005
    ..This assay also permits automation and up-scaling, making it suitable for broad HMPV seroepidemiology studies and experiments that require large scale serology, such as vaccine studies...
  18. pmc Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature
    Cindy Luongo
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    J Virol 87:1985-96. 2013
    ..The level of attenuation and genetic stability identify ΔNS2/Δ1313/1314L as a promising candidate for evaluation in pediatric phase I studies...
  19. pmc Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response
    Shirin Munir
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1001336. 2011
    ....
  20. pmc The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Building 50, Room 6511, 50 South Dr, MSC 8007, Bethesda, MD 20892 8007, USA
    J Virol 78:6927-37. 2004
    ....
  21. pmc Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates
    Cindy Luongo
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    Vaccine 27:5667-76. 2009
    ....
  22. pmc Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics
    Cindy Luongo
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    J Virol 86:10792-804. 2012
    ....
  23. pmc Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 8007, USA
    J Virol 81:6057-67. 2007
    ..Adaptation involving the functional loss of a gene is unusual for an RNA virus...
  24. ncbi request reprint Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 8007, USA
    Virology 321:247-59. 2004
    ....
  25. pmc Evaluation of pneumonia virus of mice as a possible human pathogen
    Linda G Brock
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:5829-43. 2012
    ..The absence of PVM-specific antibodies and restriction in nonhuman primates makes PVM unlikely to be a human pathogen...
  26. ncbi request reprint Genetic diversity between human metapneumovirus subgroups
    Stephane Biacchesi
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Virology 315:1-9. 2003
    ..It is reasonable to anticipate that the two genetic subgroups of HMPV represent antigenic subgroups approximately comparable to those of HRSV...
  27. pmc Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines
    Ruth A Karron
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public HealthBaltimore, Maryland, USA
    J Infect Dis 207:1773-9. 2013
    ..Several promising live-attenuated RSV vaccines are in development. Defining additional markers of attenuation could enhance clinical trials...
  28. pmc Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques
    Sunil K Khattar
    Virginia Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
    PLoS ONE 8:e75456. 2013
    ..This suggests that they are not likely to significantly infect primates in nature, and represent promising attenuated candidates for vector development. ..
  29. pmc The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death
    Eric C Freundt
    Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:1097-109. 2010
    ..These results establish an important role for ORF 3a in SARS-CoV-induced cell death, Golgi fragmentation, and the accumulation of intracellular vesicles...
  30. pmc Identification of a novel virulence factor in recombinant pneumonia virus of mice
    Christine D Krempl
    Department of Virology, Institute for Medical Microbiology and Hygiene, University of Freiburg, Freiburg, Germany
    J Virol 81:9490-501. 2007
    ..In addition to its intrinsic interest, a recombinant virus that replicates with wild-type-like efficiency but does not cause disease defines optimal properties for vaccine development...
  31. pmc Recovery of avian metapneumovirus subgroup C from cDNA: cross-recognition of avian and human metapneumovirus support proteins
    Dhanasekaran Govindarajan
    Virginia Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, MD 20742, USA
    J Virol 80:5790-7. 2006
    ..These results indicate a close functional relationship between AMPV/CO and HMPV...
  32. pmc Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV
    Ulrike Schmidt
    Institute of Molecular Biology, Federal Research Centre for Virus Diseases of Animals, D 17498 Insel Riems, Germany
    J Virol 76:12355-9. 2002
    ..Neutralizing antibodies were induced by rBRSV and rBRSVDeltaG. Thus, the BRSV attachment glycoprotein G seems to be dispensable in vaccinating calves against BRSV...
  33. pmc Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus
    Guillermina A Melendi
    Fundacion INFANT, Buenos Aires, Argentina
    J Virol 81:11461-7. 2007
    ..An understanding of the CTL response against hMPV is important for developing preventive and therapeutic strategies against the virus...
  34. ncbi request reprint A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and funct
    Patricia König
    Institute of Molecular Biology, Friedrich Loeffler Institutes, Federal Research Centre for Virus Diseases of Animals, 17493 Greifswald Insel Riems, Germany
    J Gen Virol 85:1815-24. 2004
    ....